PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

NCT00455546 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease (CAD)

Interventions

DRUG: A-002

Sponsor

Anthera Pharmaceuticals